Status:
RECRUITING
Life Following Excision of Neuroendocrine Tumors
Lead Sponsor:
Sunnybrook Health Sciences Centre
Conditions:
Neuroendocrine (NE) Tumors
Neuroendocrine Tumor GEP Grade 1-3
Eligibility:
All Genders
18+ years
Brief Summary
Neuroendocrine tumors (NETs), often seen as "chronic cancer" present a survival paradox with relatively prolonged patient survival despite active disease. Treatment strategies emphasize management ove...
Detailed Description
Background Neuroendocrine neoplasms (NENs) are a unique group of malignancies distinguished by their more indolent biology and endocrine secretion.1 Because of indolent biology, patients with well-di...
Eligibility Criteria
Inclusion
- Age \>18 years old
- Diagnosis of well-differentiated grade 1 to 3 NETs via histopathology (biopsy) or imaging (measurable tumor on CT or MRI with avidity on SSTR-PET scan).
- Consents to surgery for resection of localized, loco-regional, or metastatic gastro-enteric (midgut) and pancreatic neuroendocrine tumor (GEP-NET).
Exclusion
- Pre-operative diagnosis of neuroendocrine carcinoma on histopathology (biopsy) or imaging (measurable tumor on CT or MRI with avidity on FDG-PET scan and no avidity on SSTR-PET scan).
- Declines surgery.
- Unable to respond to study questionnaires (not proficient in local language).
Key Trial Info
Start Date :
April 28 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
246 Patients enrolled
Trial Details
Trial ID
NCT06981455
Start Date
April 28 2025
End Date
December 31 2028
Last Update
May 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5